SBIDDS
MCID: SHR102
MIFTS: 43

Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures (SBIDDS) malady

Categories: Genetic diseases, Bone diseases

Aliases & Classifications for Short Stature, Brachydactyly, Intellectual Developmental...

Aliases & Descriptions for Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures:

Name: Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures 54 66
Bone Diseases 42 69
Sbidds 66

Classifications:



External Ids:

MedGen 40 CN238697
ICD10 33 M89 M89.8

Summaries for Short Stature, Brachydactyly, Intellectual Developmental...

UniProtKB/Swiss-Prot : 66 Short stature, brachydactyly, intellectual developmental disability, and seizures: An autosomal recessive disease characterized by developmental delay, learning disabilities, mild mental retardation, delayed speech, and skeletal abnormalities. Skeletal features include short stature, brachydactyly, and short metacarpals and metatarsals.

MalaCards based summary : Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures, also known as bone diseases, is related to ischemic bone disease and dysbaric osteonecrosis, and has symptoms including back pain, muscle cramp and sciatica. An important gene associated with Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are Cytokine Signaling in Immune system and RANK Signaling in Osteoclasts. The drugs Nitric Oxide and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are growth/size/body region and hematopoietic system

Related Diseases for Short Stature, Brachydactyly, Intellectual Developmental...

Diseases related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 202)
id Related Disease Score Top Affiliating Genes
1 ischemic bone disease 32.2 BGLAP FGF23 TNFRSF11A TNFRSF11B TNFSF11
2 dysbaric osteonecrosis 30.8 BGLAP TNFRSF11A TNFRSF11B TNFSF11
3 celiac disease 29.1 BGLAP TNFRSF11B TNFSF11
4 rheumatoid arthritis 28.8 BGLAP TNFRSF11A TNFRSF11B TNFSF11
5 parathyroid carcinoma 28.7 BGLAP FGF23
6 intrahepatic cholestasis 28.6 BGLAP TNFRSF11A TNFRSF11B TNFSF11
7 polycystic bone disease 11.8
8 osteogenesis imperfecta 11.6
9 osteopetrosis 11.4
10 gorham's disease 11.2
11 paget disease of bone 5, juvenile-onset 11.2
12 osteitis fibrosa 11.1
13 paget's disease of bone 11.1
14 col1a1/2-related osteogenesis imperfecta 10.8
15 renal osteodystrophy 10.7
16 osteonecrosis 10.7
17 alkaptonuria 10.7
18 osteonecrosis of the jaw 10.7
19 acrocapitofemoral dysplasia 10.6
20 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 1 10.6
21 cystic angiomatosis of bone, diffuse 10.6
22 inclusion body myopathy with early-onset paget disease and frontotemporal dementia 10.6
23 paget disease of bone 5, juvenile 10.6
24 spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures 10.4
25 hypophosphatasia, infantile 10.4
26 hypophosphatasia, childhood 10.4
27 hypophosphatasia, adult 10.4
28 spondylometaepiphyseal dysplasia, short limb-hand type 10.4
29 gaucher disease, type i 10.4
30 hyperparathyroidism, familial primary 10.4
31 spondyloepimetaphyseal dysplasia 10.4
32 paget disease of bone 3 10.4
33 spondyloepimetaphyseal dysplasia, missouri type 10.4
34 opsismodysplasia 10.4
35 hypophosphatemic rickets, autosomal dominant 10.4
36 smed strudwick type 10.4
37 spondylometaphyseal dysplasia, kozlowski type 10.4
38 parastremmatic dwarfism 10.4
39 multiple synostoses syndrome 3 10.4
40 spondyloepimetaphyseal dysplasia, aggrecan type 10.4
41 spondyloepimetaphyseal dysplasia with joint laxity, type 2 10.4
42 small patella syndrome 10.4
43 multiple synostoses syndrome 1 10.4
44 paget disease of bone 2, early-onset 10.4
45 multiple synostoses syndrome 2 10.4
46 spondyloepimetaphyseal dysplasia, x-linked 10.4
47 osteochondritis dissecans 10.4
48 osteochondrosis 10.4
49 cole-carpenter syndrome 10.4
50 bone remodeling disease 10.4

Graphical network of the top 20 diseases related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures:



Diseases related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures

Symptoms & Phenotypes for Short Stature, Brachydactyly, Intellectual Developmental...

Clinical features from OMIM:

617157

UMLS symptoms related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures:


back pain, muscle cramp, sciatica

MGI Mouse Phenotypes related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.87 CD36 FGF23 OSTM1 PRMT7 TNFRSF11A TNFRSF11B
2 hematopoietic system MP:0005397 9.8 CD36 FGF23 OSTM1 PRMT7 TNFRSF11A TNFRSF11B
3 immune system MP:0005387 9.63 CD36 FGF23 OSTM1 TNFRSF11A TNFRSF11B TNFSF11
4 limbs/digits/tail MP:0005371 9.35 FGF23 OSTM1 TNFRSF11A TNFRSF11B TNFSF11
5 skeleton MP:0005390 9.17 TNFSF11 CD36 FGF23 OSTM1 PRMT7 TNFRSF11A

Drugs & Therapeutics for Short Stature, Brachydactyly, Intellectual Developmental...

Drugs for Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4,Phase 3,Phase 2 10102-43-9 145068
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
4
Zinc Approved Phase 4,Phase 3,Phase 2,Early Phase 1 7440-66-6 32051 23994
5
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
6
Progesterone Approved, Vet_approved Phase 4,Phase 3 57-83-0 5994
7
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492
8
Testosterone Approved, Investigational Phase 4,Phase 2,Phase 3 58-22-0 6013
9
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
10
Methotrexate Approved Phase 4,Phase 2,Phase 3,Phase 1 1959-05-2, 59-05-2 126941
11
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
12
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
13
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 59467-70-8 4192
14
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
15
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
16
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
17
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 85721-33-1 2764
18
Sulfasalazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 599-79-1 5353980 5359476
19
Atenolol Approved Phase 4,Phase 3,Phase 2 29122-68-7 2249
20
Isosorbide Dinitrate Approved Phase 4,Phase 3 87-33-2 6883
21
Acetylcholine Approved Phase 4 51-84-3 187
22
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
23
Alendronate Approved Phase 4,Phase 2,Phase 3,Phase 1 121268-17-5, 66376-36-1 2088
24
Busulfan Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 55-98-1 2478
25
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
26
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
27
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 185243-69-0
28
rituximab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 174722-31-7 10201696
29
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 50-23-7 5754 657311
30
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
31
Infliximab Approved Phase 4,Phase 2,Phase 3,Phase 1 170277-31-3
32
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
33
Pamidronate Approved Phase 4,Phase 3,Phase 2,Phase 1 40391-99-9 4674
34
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 50-24-8 5755
35
Sevelamer Approved Phase 4,Phase 3,Phase 2 52757-95-6, 152751-57-0 3085017
36
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
37
Etidronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 7414-83-7, 2809-21-4 3305
38
Calcium carbonate Approved Phase 4,Phase 2,Phase 3,Phase 1 471-34-1
39
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
40
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
41
Teriparatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52232-67-4 16133850
42
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2 120511-73-1 2187
43
Tranexamic Acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 1197-18-8 5526
44
Vancomycin Approved Phase 4,Phase 3,Phase 2,Early Phase 1 1404-90-6 441141 14969
45
Sulfamethoxazole Approved Phase 4,Phase 2,Early Phase 1 723-46-6 5329
46
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
47
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 2078-54-8 4943
48
Thiotepa Approved Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
49
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
50
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 124-94-7 31307

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus Unknown status NCT02011620 Phase 4
2 The Effects of Potassium Citrate on Bone Metabolism Unknown status NCT00357331 Phase 4
3 Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition Unknown status NCT02005302 Phase 4
4 Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients Unknown status NCT00889629 Phase 4
5 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4
6 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4
7 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
8 Osteoporosis and Dental Implant Unknown status NCT00727493 Phase 4
9 Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis Unknown status NCT01675297 Phase 4
10 To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women Unknown status NCT01904110 Phase 4
11 The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4
12 Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans? Unknown status NCT02090244 Phase 4
13 Oral Versus Intravenous Antibiotics for Bone and Joint Infections (OVIVA B&J) Unknown status NCT00974493 Phase 4
14 Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis Unknown status NCT00265252 Phase 4
15 Effect of Human Thrombin With Gelatin Matrix on Perioperative Blood Loss in Scoliosis Surgery Unknown status NCT01451788 Phase 4
16 Tranexamic Acid (TXA) Versus Epsilon Aminocaproic Acid (EACA) Versus Placebo for Spine Surgery Unknown status NCT00958581 Phase 4
17 A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height Unknown status NCT00840944 Phase 4
18 Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo Unknown status NCT01945788 Phase 4
19 Pulmonary Mechanics During Minimally Invasive Repair of Pectus Excavatum Unknown status NCT01486953 Phase 4
20 Evaluation of Bone Union Following Anterior Cervical Fusion Using a NovoMax™ Unknown status NCT02425514 Phase 4
21 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4
22 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
23 Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
24 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4
25 A Randomised Single Centre Study to Compare the Long-Term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement Unknown status NCT00208442 Phase 4
26 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4
27 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4
28 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
29 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4
30 Danish Multicenter Study of Adalimumab in Spondyloarthritis Unknown status NCT00477893 Phase 4
31 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
32 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4
33 Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy Unknown status NCT01204008 Phase 4
34 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4
35 Effects of Different Anti-rheumatic Treatments of Arthritis on Antibody Response Following Pneumococcal Vaccination Using Prevenar® Unknown status NCT00828997 Phase 4
36 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4
37 How Bone is Made in Children Receiving Dialysis Unknown status NCT01799317 Phase 4
38 Efficacy and Safety of SurgiFill™ on Spinal Fusion Unknown status NCT02466048 Phase 4
39 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4
40 Treatment of Infertility by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells Unknown status NCT02204358 Phase 4
41 Effect of Actonel on Periodontal Health of Postmenopausal Women Unknown status NCT00594334 Phase 4
42 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4
43 Bone Quality and Quantity Following Guided Bone Regeneration Prior to Dental Implant Placement Unknown status NCT01603693 Phase 4
44 Alendronate for Vascular Calcification in Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4
45 Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients Completed NCT02853539 Phase 4
46 Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB) Completed NCT00774020 Phase 4
47 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4
48 Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder Completed NCT01633853 Phase 4
49 Re-treatment of Patients With Paget's Disease Using Zoledronic Acid Completed NCT00740129 Phase 4
50 Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid Completed NCT00172029 Phase 4

Search NIH Clinical Center for Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: bone diseases

Genetic Tests for Short Stature, Brachydactyly, Intellectual Developmental...

Anatomical Context for Short Stature, Brachydactyly, Intellectual Developmental...

MalaCards organs/tissues related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures:

39
Bone

Publications for Short Stature, Brachydactyly, Intellectual Developmental...

Variations for Short Stature, Brachydactyly, Intellectual Developmental...

UniProtKB/Swiss-Prot genetic disease variations for Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures:

66
id Symbol AA change Variation ID SNP ID
1 PRMT7 p.Arg32Thr VAR_076329 rs149170494
2 PRMT7 p.Arg387Gly VAR_076330 rs762515973
3 PRMT7 p.Trp494Arg VAR_076331 rs751670999

ClinVar genetic disease variations for Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PRMT7 NM_019023.2(PRMT7): c.1276-1G> A single nucleotide variant Pathogenic rs886039897 GRCh38 Chromosome 16, 68347630: 68347630
2 PRMT7 NM_019023.2(PRMT7): c.1480T> C (p.Trp494Arg) single nucleotide variant Pathogenic rs751670999 GRCh38 Chromosome 16, 68352314: 68352314
3 PRMT7 NM_019023.2(PRMT7): c.95G> C (p.Arg32Thr) single nucleotide variant Pathogenic rs149170494 GRCh37 Chromosome 16, 68349977: 68349977
4 PRMT7 NM_019023.2(PRMT7): c.1159A> G (p.Arg387Gly) single nucleotide variant Pathogenic rs762515973 GRCh37 Chromosome 16, 68380151: 68380151
5 PRMT7 NM_019023.2(PRMT7): c.1056-1G> T single nucleotide variant Pathogenic rs201824659 GRCh38 Chromosome 16, 68346144: 68346144

Expression for Short Stature, Brachydactyly, Intellectual Developmental...

Search GEO for disease gene expression data for Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures.

Pathways for Short Stature, Brachydactyly, Intellectual Developmental...

GO Terms for Short Stature, Brachydactyly, Intellectual Developmental...

Cellular components related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.02 BGLAP CD36 FGF23 TNFRSF11B TNFSF11

Biological processes related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-mediated signaling pathway GO:0033209 9.61 TNFRSF11A TNFRSF11B TNFSF11
2 apoptotic signaling pathway GO:0097190 9.55 TNFRSF11A TNFRSF11B
3 response to estrogen GO:0043627 9.54 BGLAP TNFRSF11B
4 monocyte chemotaxis GO:0002548 9.52 TNFRSF11A TNFSF11
5 regulation of bone mineralization GO:0030500 9.51 BGLAP FGF23
6 ossification GO:0001503 9.5 BGLAP TNFRSF11A TNFSF11
7 mammary gland alveolus development GO:0060749 9.49 TNFRSF11A TNFSF11
8 regulation of osteoclast differentiation GO:0045670 9.48 BGLAP TNFSF11
9 response to inorganic substance GO:0010035 9.46 BGLAP TNFRSF11B
10 response to magnesium ion GO:0032026 9.4 FGF23 TNFRSF11B
11 cellular response to vitamin D GO:0071305 9.37 BGLAP FGF23
12 TNFSF11-mediated signaling pathway GO:0071847 9.26 TNFRSF11A TNFSF11
13 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.16 TNFRSF11A TNFSF11
14 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 8.96 TNFRSF11A TNFSF11
15 osteoclast differentiation GO:0030316 8.8 OSTM1 TNFRSF11A TNFSF11

Molecular functions related to Short Stature, Brachydactyly, Intellectual Developmental Disability, and Seizures according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 tumor necrosis factor-activated receptor activity GO:0005031 8.62 TNFRSF11A TNFRSF11B

Sources for Short Stature, Brachydactyly, Intellectual Developmental...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....